SS创新国际
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Devices
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| SS创新国际 (SSII) | 507.24M | -42.17 | 9.51 | 0.00% |
| Abbott Laboratories (ABT) | 181.50B | 33.94 | 3.55 | 2.33% |
| Medtronic (MDT) | 121.20B | 23.34 | 2.41 | 3.01% |
| Stryker Corp (SYK) | 113.02B | 30.53 | 4.71 | 1.18% |
| Boston Scientific (BSX) | 64.33B | 17.97 | 2.58 | 0.00% |
| Edwards Lifesciences (EW) | 49.92B | 50.35 | 4.70 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算42.2%。
合理价值
While SS Innovations International Inc may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 24% discount to our quantitative fair value estimate of $3.60 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's solid growth bolsters our fair value estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 122.9% falls in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.
Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 237.4, for example, ranks in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
经济护城河
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
SS创新国际 讨论区 0 条评论